Stay updated on Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.

Latest updates to the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedRevision label updated from v3.3.1 to v3.3.2 appears on the page. This seems to be a minor site version update with no visible changes to study content or user-facing elements.SummaryDifference0.0%

- Check16 days agoChange DetectedThe Publications section now notes auto-fill from PubMed and the page revision is updated to v3.3.1.SummaryDifference0.0%

- Check23 days agoChange DetectedRemoved a general notice about government funding and NIH Clinical Center operations from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check38 days agoChange DetectedNo additions or deletions were detected; page content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check59 days agoChange DetectedUpdate of geographic region labels to Auvergne-Rhône-Alpes with city-level detail for Lyon (69008); replaces Rhône-Alpes references.SummaryDifference4%

- Check67 days agoChange Detected- Updated medical terminology from 'Medullary thyroid gland carcinoma' to 'Medullary thyroid carcinoma' and bumped version to v3.2.0.SummaryDifference0.1%

Stay in the know with updates to Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.